The AgNORs count in predicting long-term survival in serous ovarian cancer

Archives of Medical Science

Volumn 10, Issue 1, 2014, Pages 84-90

  Gottwald, Leszek ^a   Danilewicz, Marian ^a   Fendler, Wojciech ^a   Suzin, Jacek ^a   Spych, Michal ^a   Piekarski, Janusz ^a   Tylinski, Wieslaw ^a   Chalubinska, Justyna ^a   Topczewska Tylinska, Katarzyna ^a   Cialkowska Rysz, Aleksandra ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Argyrophilic; Nucleolar organizer regions; Prognostic factors; Serous ovarian cancer; Survival

Indexed keywords

PARAFFIN;

ADULT; AGED; ARGYROPHILIC NUCLEOLAR ORGANIZER REGION; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; CHROMOSOME NOR; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CANCER; OVERALL SURVIVAL; SILVER STAINING; SURVIVAL PREDICTION; VERY ELDERLY; YOUNG ADULT;

EID: 84900666393     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2013.36753     Document Type: Article

References (36)

1. Linasmita V, Pattaraarchachai J, Daengdeelert P. Prognostic factors for survival of epithelial ovarian cancer. Int J Gynaecol Obstet 2004; 85: 66-9.
2. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines for gynaecological cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obsetet 2000; 70: 209-62.
3. Ozgun MT, Turkyilmaz C. A giant ovarian mucinous cystadenoma in an adolescent: a case reprt. Arch Med Sci 2009; 5: 281-3.
4. Gora E, Zelazowski MJ, Gottwald L, Bienkiewicz A, Bednarek AK. Detection of circulating carcinoma in peripheral blood collected from patients with ovarian cancer by using different molecular markers-a preliminary report. Arch Med Sci 2006; 2: 101-7.
5. Milovic-Kovacevic M, Starnatovic L, Popov I, Radosevic-Jelic L, Kezic I. Platinum sensitive relapsed epithelial ovarian cancer: not all the patients benefit from rein-duction with carboplatin and paclitaxel. Med Sci Monit 2010; 16: CR549-54.
6. Ghazizadeh M, Sasaki Y, Araki T, Konishi H, Aihara K. Prognostic value of proliferative activity of ovarian carcinoma as revealed by PCNA and AgNOR analyses. Am J Clin Pathol 1997; 107: 451-8.
7. Kakeji Y, Korenaga D, Tsujitani S, Haraguchi M, Maeha ra Y, Sugimachi K. Predictive value of Ki-67 and argyrophilic nucleolar organizer region staining for lymph node metastasis in gastric cancer. Cancer Res 1991; 51: 3503-6.
8. Nakae S, Nakamura T, Ikegawa R, Yoshioka H, Shirono J, Tabuschi Y. Evaluation of argyrophilic nucleolar organizer region and proliferating cell nuclear antigen in colorectal cancer. J Surg Oncol 1998; 69: 28-35.
9. Mauri FA, Scampini S, Aldovini D, Ferrero S, Barbareschi M, Dalla Palma P. AgNOR distribution in serous tumours of the ovary. Pathologica 1990; 82: 487-92.
10. Gottwald L, Danilewicz M, Suzin J, Bienkiewicz A. Assessment of the AgNORs count in serous ovarian cancer. Ginekol Pol 2004; 75: 770-5.
11. Criscuolo M, Martinelli AM, Migaldi M, et al. Prognostic significance of nucleolar organizer regions in ovarian epithelial tumors. Int J Gynecol Pathol 1993; 12: 259-63.
12. Sujathan K, Kannan S, Raveendran-Pillai K, Chandralekha B, Sreedevi-Amma N, Krishnan-Nair M. Significance of AgNOR count in differentiating malignant cells from reactive mesothelial cells in serous effusions. Acta Cytologica 1996; 40: 724-8.
13. Miller B, Morris M, Silva E. Nucleolar organizer regions: a potential prognostic factor in adenocarcinoma of the endometrium. Gynecol Oncol 1994; 54: 137-41.
14. Wierzchniewska A, Wagrowska-Danilewicz M, Danilewicz M. Value of AgNOR counts and morphometric analysis of nuclear parameters in premalignant and malignant lesions of the uterine cervix. Pol J Pathol 1998; 49: 297-301.
15. Kumar A, Kushwaha AK, Kumar M, Gupta S. Argyrophilic nucleolar organizer regions: their value and correlation with clinical prognostic factors in breast carcinoma. J Surg Oncol 1997; 65: 201-4.
16. Ceccarelli C, Trere D, Santini D, Taffurelli M, Chieco P, Derenzini M. AgNORs in breast tumours. Micron 2000; 31: 143-9.
17. Chiusa L, Galliano D, Formiconi A, Di Primio O, Pich A. High and low risk prostate carcinoma determined by histologic grade and proliferative activity. Cancer 1997; 79: 1956-63.
18. Atallah AM, Tabll AA, El-Nashar E, et al. AgNORs count and DNA ploidy in liver biopsies from patients with schistosomal liver cirrhosis and hepatocellular carcinoma. Clin Biochem 2009; 42: 1616-20.
19. Nakamura M, Sano K, Kitagawa Y, Ogasawara T, Nishizawa S, Yonekura Y. Diagnostic significance of FDG-PET and argyrophylic nucleolar organizer regions (AgNORs) in oral squamous cell carcinoma. Oral Oncology 2004; 40: 190-8.
20. Alaeddini M, Khalili M, Tirgary F, Etemad-Moghadam S. Argyrophylic proteins of nucleolar organizer regions (AgNORs) in salivary gland mucoepidermoid carcinoma and its relation to histological grade. Oral Surg Oral Pathol Oral Radiol Endod 2008; 105: 758-62.
21. Sirri V, Roussel P, Hernandez-Verdun D. The AgNOR proteins: qualitative and quantitative changes during the cell cycle. Micron 2000; 31: 121-6.
22. Howell WM, Black DA. Controlled silver-staining of nucleolus organizer regions with a protective colloidal developer: a 1-step method. Experimentia 1980; 36: 1014-5.
23. Mourad WA, Setrakian S, Hales ML, Abdulla M, Trucco G. The argyrophilic nucleolar organizer regions in ductal carcinoma in situ of the breast. Cancer 1994; 74: 1739-5.
24. Ofner D, Schmid KW. Standardized AgNOR analysis: its usefulness in surgical oncology. Histochem Cell Biol 1996; 106: 193-6.
25. Crocker J, Boldy D, Egan M. How should we count AgNORs? Proposals for a standardized approach. J Pathol 1989; 158: 185-8.
26. Ploton D, Menager M, Jeannesson P, Himber G, Pigeon F, Adnet J. Improvement in the staining and in the visualization of the argyrophilic proteins of the Nucleolar Organizer Regions at the optical level. Histochem J 1986; 18: 5-14.
27. Kalloniemi OP, Punnonen R, Mattila J, Lehtinen M, Koivula T. Prognostic significance of DNA index, multiploidy and S-phase fraction in ovarian cancer. Cancer 1988; 61: 334-9.
28. Gottwald L, Danilewicz M, Suzin J, et al. Assessment of the argyrophylic nucleolar organizer regions area/nucleus ratio in ovarian serous epithelial adenomas, borderline tumors and cancers. Arch Med Sci?2013; 9: 79-85.
29. Trabucco S, Varcaccio-Garofalo G, Botticella MA, De Stefano R, Capursi T, Resta L. Expression of AgNORs in serous ovarian tumors. Eur J Gynecol Oncol 1994; 15: 222-9.
30. Zergeroglu S, Aksakal O, Demirturk F, Gokmen O. Prognostic importance of the nucleolar organizer region score in ovarian epithelial tumors. Gynecol Obstet Invest 2001; 51: 60-3.
31. Sah SP, Dawar R, Kumar L, Gupta SD. Nucleolar organizer regions as a prognostic indicator in epithelial cancers of the ovary. Int J Gynecol Pathol 2004; 23: 347-53.
32. Gottwald L, Danilewicz M, Suzin J, Bienkiewicz A. The assesment of argyrophylic nucleolar organizer regions (AgNORs) count in serous ovarian neoplasms. Prz Menopauzalny 2003; 7: 38-41.
33. Gottwald L, Danilewicz M, Suzin J, Wójcik-Krowiranda K, Bienkiewicz A. AgNORs count correlates better than grading with the effect of chemotherapy in serous ovarian cancer. Pol J Pathol 2003; 54: 239-42.
34. Cucer N, Imamoglu M, Tozak H, et al. Two-dimentional agnor evaluation as a prognostic variable in bladder carcinoma: a different approach via total agnor/nucleus area per cell. Micron 2007; 38: 674-9.
35. Muso H. Long-term prognostic factors for chemotherapy of ovarian cancer. Osaka City Med J 1998; 44: 155-71.
36. Franck J, Longuespee R, Wisztorski M, et al. MALDI mass spectrometry imaging of proteins exceeding 30 000 daltons. Med Sci Monit 2010; 16: BR293-9.